
For people with non-muscle-invasive bladder cancer, treatment can involve repeated procedures, a high risk of tumor recurrence, toxic therapies and, in some cases, removal of the bladder. Hamlet Biopharma is developing Alpha1H, a synthetic peptide inspired by a protein complex found in human breast milk. Catharina Svanborg, chair of Hamlet Biopharma, discusses how Alpha1H is designed to selectively target bladder tumor cells while sparing healthy tissue, the science that led to the program, and the clinical-development path ahead.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Neutralizing Tumor Acidity to Improve Cancer Immunotherapy

Targeting Visceral Fat with RNA Therapeutics

Engineering T-Cell Engagers for Solid Cancers

Resetting Severe Allergies at Their Cellular Source
Free AI-powered recaps of The Bio Report and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.